Skip to content

Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE

Meta-Analysis of Cell-based CaRdiac stUdiEs: ACCRUE

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01098591
Acronym
ACCRUE
Enrollment
3500
Registered
2010-04-05
Start date
2007-11-30
Completion date
2020-12-31
Last updated
2021-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Heart Disease

Keywords

meta-analysis, stem cell, cardiac, remodeling, ACCRUE

Brief summary

Numerous human cardiac stem cell studies have been published, including relatively small number of patients. Meta-analysis of randomized trials have reported safety and a 3-6% increase in global left ventricular performance after intracoronary stem cell therapy in patients with acute myocardial infarction. Since most of the studies used different type of stem cells, delivery modes, and patient population, the results are heterogenous, therefore the comparison of the results is biased regarding generalizable conclusions about the effect of treatment. The present comparative meta-analysis is based on individual patient data, and gathers and pools the raw data, and analyzes the clinical outcome, safety and efficacy of the cardiac stem cell therapy.

Detailed description

* Background: Many clinical trials and meta-analyses presented moderate but significant improvement of the left ventricular ejection fraction (LVEF) after intracoronary autologous bone-marrow (BM) or peripheral blood origin stem cells transfer. However, it remains controversial, whether this beneficial effects is comparable with the intramyocardial delivery of the stem cells, or could be maintained during moderate and long term follow-up. The BOOST trial suggested that cardiac stem cell therapy did not improve LVEF at 5-year follow-up. By contrast, BALANCE study showed a long sustained benefit of BM-stem cells treatment. Due to these divergent outcomes of the presented trials, the aim of the present meta-analysis is to compare the safety and effectiveness of the cardiac stem cell therapy in different patient population, delivery mode and cell type, to find out, which patients with which therapy mode can have the greatest benefit from cardiac stem cell therapy. * Study design: individual patient data meta-analysis * Data sources: European Centre performing human cardiac stem cell therapy have been contacted calling for participation. * Methods: Individual data gathering and entering into the database for a pooled analysis. The meta-analysis will be done in line with recommendation from the Cochrane Collaboration and the Quality of Reporting of Meta-analyses guidelines with Review Manager 5.0. Fixed-effect model will be used.

Interventions

OTHERcell therapy

Sponsors

Nantes University Hospital
CollaboratorOTHER
Oslo University Hospital
CollaboratorOTHER
Medical University of Silesia
CollaboratorOTHER
Hannover Medical School
CollaboratorOTHER
VZW Cardiovascular Research Center Aalst
CollaboratorOTHER
Cedars-Sinai Medical Center
CollaboratorOTHER
Johann Wolfgang Goethe University Hospital
CollaboratorOTHER
University of Ulm
CollaboratorOTHER
Military Medical Academy, Belgrade, Serbia
CollaboratorOTHER
Novosibirsk Scientific Research Institute for Circulatory Pathology
CollaboratorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Asklepios Kliniken Hamburg GmbH
CollaboratorOTHER
Leiden University Medical Center
CollaboratorOTHER
University of Debrecen
CollaboratorOTHER
University of Targu Mures, Romania
CollaboratorOTHER
University Clinic for Cardiology, Skopje, Republic of Macedonia
CollaboratorUNKNOWN
State Health Center, Hungary
CollaboratorOTHER
Karolinska Institutet
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
University of Oulu
CollaboratorOTHER
Odense University Hospital
CollaboratorOTHER
Minneapolis Heart Institute
CollaboratorOTHER
The University of Texas Health Science Center, Houston
CollaboratorOTHER
Klinik Hirslanden, Zurich
CollaboratorOTHER
University Hospital, Toulouse
CollaboratorOTHER
Heinrich-Heine University, Duesseldorf
CollaboratorOTHER
Medical University of Vienna
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patient included in one of the registered cell-based cardiac therapy of the participating center

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Freedom from occurrence of major adverse cardiac and cerebrovascular events (MACCE), including all-cause death, re-infarction, revascularization and stroke12 monthsMACCE is defined as all-cause death, re-infarction, revascularization and stroke

Secondary

MeasureTime frameDescription
Changes in ejection fraction12 monthsImprovement of systolic cardiac function after cell therapy
Hard clinical end point12 monthsall-cause death, re-infarction and stroke
Changes in end-diastolic volume12 monthsEnd-diastolic volume is an index of ventricular remodeling
Changes in end-systolic volume12 monthsIndex of ventricular systolic performance

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026